|
Fifth National Stakeholder Meeting, June 4, 2009
The Seattle Public Library
1000 Fourth Avenue
Seattle, WA 98104
The focus of this meeting was Goal 5 of the National Vaccine Plan: Increase global prevention of death and disease through safe and effective vaccination. The agenda is posted below (please scroll down).
The 2008 Draft Strategic National Vaccine Plan is available on the Department of Health and Human Services National Vaccine Program Office website (click here to view--by clicking this link you are leaving the IOM website and will be directed to the HHS website). Goal 5 begins on page 56.
Agenda
AUDIO FILE FOR EACH PANEL CAN BE FOUND AT THE BOTTOM OF THE PAGE
Please note: Complete participant affiliations are provoded at the end of the agenda
|
8:30 am
|
Welcome, overview, and committee introductions
Claire V. Broome, IOM Committee Chair
|
|
8:45 am
|
Panel 1– Development of new vaccines and those needed for global use
|
|
|
Moderator: Claire Broome, IOM committee chair
Topics of discussion may include:
- Setting priorities
- Scientific challenges
- Regulatory issues
- Implementation issues
- Advocacy/policy communication issues
- Role of non-Western vaccine companies as vaccine developers and suppliers for both developed and developing nations
Discussants
Norman Baylor, CBER/FDA (by phone)
Brent Burkholder, NCIRD/CDC
Thomas Cherian, WHO
Margaret McCluskey, USAID
Mark Feinberg, Merck
John Ferguson, Novartis Vaccines & Diagnostics
Orin Levine, Johns Hopkins University
Adel Mahmoud, Princeton University (by phone)
Regina Rabinovich, Gates Foundation
Jerald Sadoff, Aeras Global TB Vaccine Foundation
Theodore Tsai, Novartis
Justin Wright, BD Medical-Pharmaceutical Systems
|
|
10:30 am
|
Break
|
|
|
|
|
10:45 am
|
Panel 2 – Immunization program issues: infra-structure, communication, impact of eradication/elimination
Moderator: Milagritos Tapia, IOM committee member
Topics of discussion may include:
- Quality and safety of administration, storage, inventory management, cold chain, other infrastructure issues
- Impact of health systems "reform”,
- Are vaccines reaching those at highest risk of disease?
- Innovative approaches to target high-risk/hard-to-reach groups
- Implications of target populations with high proportion of HIV infected
Discussants
Brent Burkholder, NCIRD/CDC
Thomas Cherian, WHO
Rod Hausser, BD Medical-Pharmaceutical Systems
Orin Levine, Johns Hopkins University
Margaret McCluskey, USAID
Robert Steinglass, John Snow Inc.
Linda Venczel, Gates Foundation
|
|
|
|
|
12:30 pm
|
Lunch
|
|
|
|
|
1:30 pm
|
Panel 3 – Surveillance of safety, effectiveness, coverage, disease
Moderator: Art Reingold, IOM committee member
Topics of discussion may include:
- Immunization program monitoring and evaluation
- Coverage measurement vs disease impact
- Challenges of safety monitoring eg Yellow Fever vaccine in Africa
Discussants
Brent Burkholder, NCIRD/CDC
John Ferguson, Novartis Vaccines & Diagnostics
David Fleming, Director & Health Officer, WA
Kathy Neuzil, PATH
Robert Steinglass, John Snow Inc.
Linda Venczel, Gates Foundation
|
|
|
|
|
3:15 pm
|
Break
|
|
|
|
|
3:30 pm
|
Panel 4 – Financing vaccine development and purchase
Moderator: David Paltiel, IOM committee member
Topics of discussion may include:
- Financing new vaccine development
- financing purchase of expensive new vaccines (eg pneumococcal conjugate, HPV)
- sustainable support for new vaccines by developing countries
- experience with novel financing approaches—IIFM, AMC, Gates (pros and cons)
- Prioritizing support for optimal use of existing vaccines vs development of new vaccines
Discussants
Brent Burkholder, NCIRD/CDC
Orin Levine, Johns Hopkins University
Melinda Moree, Global Health Services
Regina Rabinovich, Gates Foundation
Jerald Sadoff, Aeras Global TB Vaccine Foundation
|
|
|
|
|
5:30 pm
|
Adjourn
|
Public comments will be accepted through June 12, 2009.
To submit comments about setting priorities in the National Vaccine Plan, please send an email to vaccineplan@nas.edu. Please note: Any comments that you submit to the committee, including your name and identifying information, will not be kept confidential and will be included in a Public Access File, as the National Academy of Sciences complies with Section 15 of the Federal Advisory Committee Act (FACA). The National Academies shall be authorized to use any such comments or submissions in accordance with the National Academies Terms of Use Statement.
Questions or comments? Please contact us!
|